DexCom, Inc. logo
DexCom, Inc. (DXCM)
Compare

DexCom, Inc. (DXCM) Average EV/EBIT Ratio

EV/EBIT Ratio

The current ev/ebit ratio for DexCom, Inc. (DXCM) is 29.06x as of Wednesday, June 10, 2026, shown against its trailing averages.

Average EV/EBIT Ratio Chart

DXCM EV/EBIT Ratio Averages

EV/EBIT RATIO CURRENT

29.06x

EV/EBIT RATIO TTM

38.74x

EV/EBIT RATIO 3Y

65.30x

EV/EBIT RATIO 5Y

101.94x

EV/EBIT RATIO 10Y

112.84x

EV/EBIT RATIO 15Y

112.84x

EV/EBIT RATIO 20Y

112.84x

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA
10,200 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Jacob Steven Leach